Cerecor signs deal with Merck for potential CNS drugs

Baltimore-based biotech firm Cerecor secured exclusive global rights to develop and market compounds that inhibit catechol-O-methyltransferase from Merck & Co. Cerecor said the agents have the potential to be used as treatments for addiction, schizophrenia and other central nervous system disorders. Cerecor will review more than 2,000 drug candidates and select some for clinical development. Merck could get milestone fees and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT